Clincosm LogoSign in Get a demo

HER2-positive Breast Cancer

Showing 1 - 25 of 200
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Breast Cancer, Advanced Breast Cancer Trial in Phoenix, Miami, Boston (Prolonged Overnight Fasting,

Not yet recruiting
  • HER2-positive Breast Cancer
  • Advanced Breast Cancer
  • Prolonged Overnight Fasting
  • +2 more
  • Phoenix, Arizona
  • +2 more
Nov 8, 2023

HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)

Completed
  • HER2-positive Breast Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023

ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.

Recruiting
  • Breast Cancer Female
  • +4 more
    • Ho Chi Minh City, Vietnam
    • +1 more
    Oct 16, 2023

    Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

    Not yet recruiting
    • Breast Cancer
    • HER2-positive Breast Cancer
    • São Paulo, Brazil
      Centro Paulista de Oncologia (Oncoclínicas)
    Oct 3, 2023

    Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

    Recruiting
    • HER2-positive Breast Cancer
    • Early-stage Breast Cancer
    • pyrotinib combined with Capecitabine
    • treatment of physician's choice
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Sep 6, 2023

    HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • LMD
    • Tucatinib 150 MG
    • +3 more
    • (no location specified)
    Aug 24, 2023

    HER2-positive Breast Cancer Trial in China (TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • TQB2440 injection + Trastuzumab + Docetaxel
    • Perjeta + Trastuzumab + Docetaxel
    • Chongqing, Chongqing, China
    • +5 more
    Aug 3, 2023

    HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Trastuzumab deruxtecan
    • Amsterdam, Netherlands
      Antoni van Leeuwenhoek
    Aug 7, 2023

    HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • 68Ga/131I-SGMIB-5F7
    • Shanghai, China
      Huashan Hospital
    Aug 1, 2023

    HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
    • (no location specified)
    Jul 20, 2023

    Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Seoul (exosome and ctDNA evaluation)

    Active, not recruiting
    • Triple Negative Breast Cancer
    • HER2-positive Breast Cancer
    • exosome and ctDNA evaluation
    • Seoul, Korea, Republic of
      Ji-Yeon Kim
    Jul 13, 2023

    Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Amsterdam (89Zr-DFO*-trastuzumab PET scan)

    Recruiting
    • Breast Cancer
    • +5 more
    • 89Zr-DFO*-trastuzumab PET scan
    • Amsterdam, Noord-Holland, Netherlands
      AmsterdamUMC
    Jul 12, 2023

    HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)

    Recruiting
    • HER2-positive Breast Cancer
    • Eribulin mesylate injection、Pertuzumab、Trastuzumab
    • Guanzhou, Guangdong, China
      LI YuDong
    Jul 13, 2023

    Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

    Active, not recruiting
    • Breast Cancer
    • HER2-positive Breast Cancer
    • Zhengzhou, Henan, China
      Henan cancer hospital
    Jun 23, 2023

    Early On-treatment Transcriptional Profiling as Predictor of

    Recruiting
    • HER2-positive Breast Cancer
    • +2 more
    • Trastuzumab (neoadjuvant)
    • +2 more
    • Hospitalet de Llobregat, Barcelona, Spain
      Institut Català d'Oncologia l'Hospitalet
    Jun 12, 2023

    Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

    Enrolling by invitation
    • Breast Cancer
    • +7 more
    • Dnipro, Ukraine
    • +1 more
    Jun 17, 2023

    Cardiotoxicity, HER2-positive Breast Cancer, Heart Failure Trial in London (Phased withdrawal of heart failure medications)

    Not yet recruiting
    • Cardiotoxicity
    • +3 more
    • Phased withdrawal of heart failure medications
    • London, United Kingdom
    • +1 more
    May 19, 2023

    HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

    Recruiting
    • HER2-positive Breast Cancer
    • +17 more
    • ALX148
    • Fam-Trastuzumab Deruxtecan-Nxki
    • Chicago, Illinois
    • +1 more
    May 19, 2023

    HER2-positive Breast Cancer Trial in Nanjing (Pyrotinib)

    Recruiting
    • HER2-positive Breast Cancer
    • Nanjing, Jiangsu, China
      JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
    Apr 26, 2023

    Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell Vaccine)

    Recruiting
    • Leptomeningeal Disease
    • +2 more
    • Dendritic Cell Vaccine
    • Tampa, Florida
      Moffitt Cancer Center
    Apr 11, 2023

    Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

    Not yet recruiting
    • Invasive Breast Cancer
    • +4 more
    • Boston, Massachusetts
    • +1 more
    Mar 20, 2023

    Patterns and Associated Outcomes in Patients of China With

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Electronic medical record and hospital information system or other available resources
    • Beijing, China
    • +6 more
    Mar 3, 2023

    Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

    Recruiting
    • Early-stage Breast Cancer
    • +4 more
    • Trastuzumab and nelatinib
    • Trastuzumab and Parstuzumab
    • Guangzhou, China
      Sun Yat-sen University Sun Yat-sen Memorial Hospital
    Mar 12, 2023

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Cessation of anti-HER2 treatment
    • Boston, Massachusetts
    • +1 more
    Feb 9, 2023